Lantheus announces FDA approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection. Learn more.

Because we’re making headlines

Please visit our investor site for a complete list of recent and archived press releases, follow us on LinkedIn for social media updates and browse below for additional media resources.

Latest press releases

See all press releases

Press release

April 24, 2023

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Read more

Press release

April 20, 2023

Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time

Read more

Press release

March 17, 2023

Lantheus Announces Two Key Executive Promotions

Read more

Additional resources

Media library

Images, videos and other assets bring news about Lantheus to life.

Events

Events allow us to connect with our people, patients and partners.

Investors

All investor resources can be found on our dedicated investor website.

Contact

Media

Melissa Downs
Executive Director
External Communications

646-975-2533

media@lantheus.com

Investors

Mark Kinarney
Vice President
Investor Relations

978-671-8842

ir@lantheus.com